Salvage therapy for recurrence of bladder cancer: Do we need a uniform approach?

Research output: Contribution to journalArticlepeer-review


The activity of chemotherapy as salvage therapy for recurrent bladder cancer has been well defined, although the optimum therapy combination is less clear. Since the early nineties several cisplatin based regimens have been compared but no one regimen has reported a superior benefit. Currently, regimens such as methotrexate, vinblastine, doxorubicin and cisplatin and gemcitabine-cisplatin should be considered two equal alternatives in patients eligible for cisplatin, but the differing toxicity profiles should be evaluated in the choice of treatment. The use of a triple combination with paclitaxel, gemcitabine and cisplatin should be avoided in clinical practice, although its use may be carefully considered in patients needing a rapid downsizing of disease and with primary bladder tumor. Despite this evidence, several questions remain, and there is a need for answers in the future.

Original languageEnglish
Pages (from-to)397-399
Number of pages3
JournalExpert Review of Clinical Pharmacology
Issue number4
Publication statusPublished - 2014


  • advanced disease
  • bladder cancer
  • chemotherapy
  • cisplatin
  • first line
  • gemcitabine
  • MVAC
  • paclitaxel

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Medicine(all)


Dive into the research topics of 'Salvage therapy for recurrence of bladder cancer: Do we need a uniform approach?'. Together they form a unique fingerprint.

Cite this